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SIR—Recently, a rare functional variant, I425V, in the serotonin transporter gene (SLC6A4) has been 
reported to be associated with a complex neuropsychiatric phenotype that includes obsessive-
compulsive disorder (OCD), alcohol abuse/dependence, anorexia nervosa, and pervasive 
developmental disorder (PDD).1 Our study, performed in a large population of patients with these 
disorders, confirms the occurrence and the segregation of V425 in OCD.  
The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) has been implicated in numerous 
psychiatric disorders, mostly because of the efficacy of serotonin reuptake inhibitors (SRIs). Among 
the polymorphisms identified in SLC6A4, three have been shown to be functional. The rare I425V 
variation, located in exon 9, increases the transport activity of the protein2, whereas the two more 
frequent polymorphisms, 5-HTTLPR located in the 5’-UTR of the gene, and STin2 located in intron 2, 
modify the transcriptional activity of the gene3,4. Despite a large number of studies, the functional 
implications of the two frequent SLC6A4 polymorphisms in psychiatric disorders are still a matter of 
debate. In the present study, we sought to further explore the influence of the rare but clearly 
functional I425V variant in a large sample of patients with OCD and other psychiatric conditions 
previously reported in the two families carrying I425V, i.e., PDD, anorexia nervosa, and alcohol 
abuse/dependence. 
To be included in the study, patients had to meet the DSM-IV criteria for OCD, anorexia nervosa, 
alcohol abuse/dependence, or PDD. The diagnosis of PDD was confirmed using the Autism 
Diagnostic Interview-Revised.5 For the other disorders, lifetime psychiatric evaluation was carried out 
using the Diagnostic Interview for Genetic Studies (DIGS)6 for adult patients, or the Kiddie Schedule 
for Affective Disorders and Schizophrenia for children.7 Healthy controls were included after being 
interviewed with the DIGS and the Family Interview for Genetic Studies8 to confirm the absence of 
both personal and family history of major psychiatric disorders. The local Research Ethics Boards 
reviewed and approved the study. 
The V425 was found in 3/254 probands with OCD, 1/284 with PDD, 1/124 with anorexia nervosa, 
in 1/285 healthy controls, but not in alcohol abusers/dependents (0/128) (Table 1). In OCD family 1, 
V425 was transmitted by the father who also had a lifetime history of OCD and single phobia. The 
paternal grandfather was alcoholic and tobacco dependant. No genotypic information was available for 
the paternal grandparents since the grandfather died of throat cancer and the grandmother of breast 
cancer. In OCD family 2, the mother and two siblings of the proband had committed suicide and the 
father was also dead, so no genotypic information was available for these individuals. OCD case 1 had 
only one brother, who committed suicide some years ago, so no genotypic information was available 
for him. No other clinical data were available concerning the first-degree relatives of OCD case 1. In 
PDD family 1, V425 was transmitted by the father and was present in the proband and two brothers. 
The father and one of the brothers carrying the V425 were both alcohol dependent. However, the 
youngest brother (19 years old), also carrying the V425 variant, did not suffer from alcoholism or any 
other psychiatric disorder at the time of evaluation. 
Our results are in accordance with those previously reported by Ozaki et al1 on four points. First, 
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we report a possibly higher occurrence of the V425 variant in OCD compared to controls. Although 
the variant is rare, the combined results of the two studies indicate a significantly higher frequency of 
V425 in OCD compared to controls1,9 (5/457 vs. 2/884, Fisher exact test, P= 0.02). Second, despite the 
limited clinical and genotypic information on the families carrying the V425 variant, our results 
suggest a possible co-segregation between the V425 and neuropsychiatric phenotypes, specifically in 
OCD. Third, Ozaki et al. hypothesized that the V425 variant may confer treatment-resistance to SRIs. 
This was indirectly supported by our findings since all OCD probands carrying the V425 variant in our 
study were considered resistant to SRIs, i.e., the severity of their obsessive and compulsive symptoms 
decreased less than 25% with multiple trials of a high dose of SRIs and a good compliance. 
Specifically, the three probands with OCD carrying the variant showed poor or no response to multiple 
trials of SRIs at adequate doses over several years. Fourth, the analysis of the two additional 
polymorphisms of the SCL6A4 gene indicated that the V425 polymorphism might be associated with 
the L allele of 5-HTTLPR. However, our results do not confirm the hypothesis of a combined gain of 
function effect of both V425 and L/L genotype as a genetic risk for OCD, since this combined 
genotype was not present in all affected patients and, by contrast, was present in the control subject 
carrying the V425 variant.  
In conclusion, our results are similar to those of the original report by Ozaki et al. and, therefore, 
lend support for a role of SLC6A4 V425 in the susceptibility to complex neuropsychiatric phenotypes. 
However, due to its global low frequency and to the fact that it was detected in a few controls, the role 
of V425 remains uncertain and should be interpreted with caution. We encourage other investigators, 
especially in the field of OCD, to screen for V425 in their samples. Indeed, the replication of these 
findings could ultimately implicate SLC6A4 as a true susceptibility gene to complex neuropsychiatric 
disorders, and consequently shed further light on the results obtained with the more frequent 
polymorphisms.  
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Table 1   SCL6A4 genotypes and clinical features of the subjects included in the study 
  SCL6A4 genotypes a  Clinical features 
  5’-UTR    5-HTTLPR 
Intron 2 
VNTR STin2 
Exon 9 
I425V  Lifetime axis I disorders  Response to SRIs
b 
OCD (n=254)        
 OCD family 1        
  Father L/S 12/12 Ile/Val  OCD, simple phobia  Spontaneous remission 
  Mother L/S 10/12 Ile/Ile  No disorder   
  
Proband 
(male, 29 years) 
L/L 10/12 Ile/Val  OCD, panic disorder, simple 
phobia, dysthymia 
 Resistance to SRIs – 
never achieved clinical 
remission 
  Sister L/L 10/12 Ile/Ile  no disorder   
 OCD family 2        
  
Proband 
(female, 61years) 
L/L 10/12 Ile/Val  OCD, dysthymia  Resistance to SRIs—
never achieved clinical 
remission 
  Daughter — — Ile/Ile  No disorder   
 
OCD case 1 
(female, 33 years) 
L/S 12/12 Ile/Val  OCD, major depressive 
disorder 
 Resistance to SRIs—
never achieved clinical 
remission 
Pervasive developmental disorder (n=284)       
 PDD family 1        
  Father L/L 10/12 Ile/Val  Alcohol-dependence, depression   
  Mother L/S 12/12 Ile/Ile  No disorder   
  Proband (male, 29 years) 
L/S 12/12 Ile/Val  Autism, severe mental 
retardation, echolalic speech   
  Sister L/S 10/12 Ile/Ile  No disorder   
  Brother L/S 10/12 Ile/Ile  No disorder   
  
Brother (22 years) L/S 12/12 Ile/Val  Drug and alcohol-
dependence, depression, 
ADHD 
  
  Brother (19 years) L/S 12/12 Ile/Val  No disorder   
Anorexia nervosa (n=124)        
 Anorexia nervosa family 1        
  Father L/S 12/12 Ile/Val  No clinical evaluation   
  Mother L/S 12/12 Ile/Ile  No clinical evaluation   
  Proband  (female, 19 years) 
L/S 12/12 Ile/Val  Anorexia nervosa   
Alcohol–dependence (n=128)        
 None carried the mutation        
Healthy controls (n=285)        
 T115 (male, 33 years) L/L 10/12 Ile/Val  No disorder   
ADHD, attention deficit hyperactivity disorder; OCD, obsessive-compulsive disorder; PDD, pervasive developmental disorder; SRIs, 
serotonin reuptake inhibitors. 
a The polymorphisms 5-HTTLPR and STin2 were genotyped using methods described previously.10 Genotyping of the I425V 
variation was performed by direct sequencing. 
b Benefits in symptom severity were less than 25% with multiple trials of a high dose of SRIs and a good compliance. 
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